In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for $300m upfront. The acquisition of CMG1A46, ...

GSK inks agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline: London, UK Thursday, October 31, 2024, 10:00 Hrs [IST] GSK plc and Chimagen Bioscien ...

UK pharma major GSK is to buy CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from privately-held ...

The candidate in question is CMG1A46, a dual CD19- and CD20-targeted T cell engager that Chimagen Biosciences is currently evaluating in phase 1 trials for leukemia and lymphoma. However, GSK has ...

(Alliance News) - GSK PLC on Tuesday said that it has signed a deal to buy CMG1A46 from Chimagen Biosciences for USD300 million upfront. The London-based pharmaceutical and biotechnology firm plans to ...

GSK is acquiring CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager. GSK plans to develop and commercialise CMG1A46 with a focus on B cell-driven autoimmune diseases, such as ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...

LONDON, UK I9, 2024 I GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, today announced an ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for $300m upfront. The acquisition of ...